This article describes a method for the isolation and purification of intact Legionella-containing vacuoles (LCVs) from amoeba and macrophages. The two-step protocol comprises LCV enrichment by immuno-magnetic separation using an antibody against a bacterial LCV marker and further purification by density gradient centrifugation.
The opportunistic pathogen Legionella pneumophila is an amoeba-resistant bacterium, which also replicates in alveolar macrophages thus causing the severe pneumonia “Legionnaires’ disease”1. In protozoan and mammalian phagocytes, L. pneumophila employs a conserved mechanism to form a specific, replication-permissive compartment, the “Legionella-containing vacuole” (LCV). LCV formation requires the bacterial Icm/Dot type IV secretion system (T4SS), which translocates as many as 275 “effector” proteins into host cells. The effectors manipulate host proteins as well as lipids and communicate with secretory, endosomal and mitochondrial organelles2-4.
The formation of LCVs represents a complex, robust and redundant process, which is difficult to grasp in a reductionist manner. An integrative approach is required to comprehensively understand LCV formation, including a global analysis of pathogen-host factor interactions and their temporal and spatial dynamics. As a first step towards this goal, intact LCVs are purified and analyzed by proteomics and lipidomics.
The composition and formation of pathogen-containing vacuoles has been investigated by proteomic analysis using liquid chromatography or 2-D gel electrophoresis coupled to mass-spectrometry. Vacuoles isolated from either the social soil amoeba Dictyostelium discoideum or mammalian phagocytes harboured Leishmania5, Listeria6, Mycobacterium7, Rhodococcus8, Salmonella9 or Legionella spp.10. However, the purification protocols employed in these studies are time-consuming and tedious, as they require e.g. electron microscopy to analyse LCV morphology, integrity and purity. Additionally, these protocols do not exploit specific features of the pathogen vacuole for enrichment.
The method presented here overcomes these limitations by employing D. discoideum producing a fluorescent LCV marker and by targeting the bacterial effector protein SidC, which selectively anchors to the LCV membrane by binding to phosphatidylinositol 4-phosphate (PtdIns(4)P)3,11 . LCVs are enriched in a first step by immuno-magnetic separation using an affinity-purified primary antibody against SidC and a secondary antibody coupled to magnetic beads, followed in a second step by a classical Histodenz density gradient centrifugation12,13 (Fig. 1).
A proteome study of isolated LCVs from D. discoideum revealed more than 560 host cell proteins, including proteins associated with phagocytic vesicles, mitochondria, ER and Golgi, as well as several GTPases, which have not been implicated in LCV formation before13. LCVs enriched and purified with the protocol outlined here can be further analyzed by microscopy (immunofluorescence, electron microscopy), biochemical methods (Western blot) and proteomic or lipidomic approaches.
1. Preparations for LCV Isolation
2. LCV Isolation
3. Microscopic Analysis of the Collected Samples
4. Representative Results
The quality and yield of the LCV purification by immuno-affinity separation and density gradient centrifugation can be followed by fluorescence microscopy (Fig. 1). An overview of samples collected during the LCV isolation from D. discoideum or macrophages is shown (Fig. 2). The homogenate of L. pneumophila-infected phagocytes shows intact LCVs, but also a lot of cell debris and extracellular bacteria. After pelleting the sample, the image is similar to the homogenate, sometimes a bit denser. Since intact LCVs should stick to the column, the flow-through contains mostly extracellular bacteria and cell debris. After eluting the sample from the column, the eluate contains intact LCVs in large amounts. In our hands, the LCV purification appears to be more effective for D. discoideum than for macrophages. In D. discoideum the pathogen vacuoles appear rounder and the yield of isolated LCVs is more than 10 times higher compared with macrophages (Fig. 3). In intact macrophages LVCs stained with different antibodies also appear more irregularly shaped.
Figure 1. Schematic overview of LCV isolation. A) Isolation of LCVs by immuno-magnetic separation using an affinity-purified antibody against the bacterial effector protein SidC, localizing exclusively to the LCV membrane. A secondary MACS micro bead-coupled antibody and a magnet are used to isolate LCVs from cell debris. B) After immuno-magnetic separation LCVs are further purified by Histodenz density gradient centrifugation. LCVs are enriched in fraction 4.
Figure 2. Samples collected during LCV purification. Images from homogenate, pellet, flow-through and eluate from D. discoideum or macrophages are depicted. The samples show L. pneumophila producing DsRed-Express (red) in D. discoideum producing GFP-calnexin signal (green, upper panel) or in macrophages stained with an anti-SidC antibody (cyan, lower panel). Bars, 10 μm.
Figure 3. Purified LCVs from D. discoideum or macrophages. The samples show fraction 4 after Histodenz density gradient centrifugation of L. pneumophila producing DsRed-Express (red) in (A) D. discoideum producing GFP-calnexin signal (green) or (B) in macrophages stained with an anti-SidC antibody (cyan). Bars, 10 μm.
In contrast to previously published methods, this protocol is based on two steps, first the separation of LCVs by an immuno-magnetic approach, and second, the purification of LCVs by density gradient centrifugation. The LCV isolation can be easily followed by fluorescence microscopy, when either fluorescently labeled bacteria and GFP-producing cells or antibody staining is used. The protocol described here is a simple, straight-forward method, which results in the enrichment of LCVs with high purity. Importantly, the protease inhibitor in the homogenization buffer is required for RAW264.7 macrophages, but optional for D. discoideum 13.
In principle, the protocol can be adopted for other pathogens or host cells, as long as a specific, selectively localizing marker is present, which is needed for the separation step. Ideally, the distinct marker is of bacterial origin, transported to the vacuole membrane, and selectively localizing there. Targeting a host cell marker likely results in the undesired co-purification of the pathogen vacuole with other host cell compartments.
Once a distinctive marker of the pathogen vacuole is identified, a suitable polyclonal or monoclonal antibody has to be raised. For every primary antibody the concentration and the blocking reagent should be optimized, as blocking reagents other than FCS could be more appropriate (e.g. BSA, de-lipidated milk, other commercially available blocking reagents).
Another critical point is the infectivity of the pathogen. The bacteria used for infection should be in their most infective stage. L. pneumophila, e.g., needs to be grown to the post-exponential/early stationary growth phase in liquid culture. Under these conditions, the bacteria are also morphologically uniform (~2 x 0.5 μm), as opposed to bacteria grown on CYE agar plates. Furthermore, antibiotics possibly used in the cell culture medium must be removed prior to an infection to avoid low infectivity and harm to the bacteria. To avoid a negative effect on the uptake efficiency, the phagocytes should have reached a confluency of approximately 80% (not more) at the time of infection. Finally, although an incubation period of 1 hr is the standard infection time for L. pneumophila, yielding a rather homogenous and robust population of LCVs, other time points can be chosen for proteomic or biochemical studies on LCV formation13.
Once the above method is established for a given pathogen-host cell pair, it is also possible to test bacterial mutant strains and/or different host cells, including D. discoideum defined deletion mutants. In general, pathogen vacuoles purified with this protocol can be analyzed by different methods, including microscopy (fluorescence and electron microscopy), biochemical assays (Western blot), as well as proteomics and lipidomics. For the latter methods, it is advisable to coordinate with the person in charge of the proteomics/ lipidomics analysis the buffer conditions, sample amounts and downstream processing of purified pathogen vacuoles.
The authors have nothing to disclose.
Research in our lab was supported by the Max von Pettenkofer Institute, Ludwig-Maximilians University Munich, the German Research Foundation (DFG, HI 1511/3-1) and the Bundesministerium für Bildung und Forschung (BMBF) “Medical Infection Genomics” initiative (0315834C).